LLY

1,160.33

+2.68%↑

JNJ

232.05

-0.26%↓

ABBV

222.8

-2%↓

UNH

403.54

+0.81%↑

AZN

183.87

-1.12%↓

LLY

1,160.33

+2.68%↑

JNJ

232.05

-0.26%↓

ABBV

222.8

-2%↓

UNH

403.54

+0.81%↑

AZN

183.87

-1.12%↓

LLY

1,160.33

+2.68%↑

JNJ

232.05

-0.26%↓

ABBV

222.8

-2%↓

UNH

403.54

+0.81%↑

AZN

183.87

-1.12%↓

LLY

1,160.33

+2.68%↑

JNJ

232.05

-0.26%↓

ABBV

222.8

-2%↓

UNH

403.54

+0.81%↑

AZN

183.87

-1.12%↓

LLY

1,160.33

+2.68%↑

JNJ

232.05

-0.26%↓

ABBV

222.8

-2%↓

UNH

403.54

+0.81%↑

AZN

183.87

-1.12%↓

Home・Aandelen Lijst・Merck & Co Inc.

Merck & Co Inc.

Open

SectorGezondheidszorg

119.77 -0.96

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

119.77

Max

122.57

Belangrijke statistieken
By Trading Economics
Inkomsten	-7.2B -4.2B
Verkoop	-114M 16B
K/W Sectorgemiddelde	32.442 49.888
EPS	-1.28
Dividendrendement	2.76
Winstmarge	-26.053
Werknemers	73,000
EBITDA	-6.2B -1.9B

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+13.01% upside

Dividenden
By Dow Jones
Dividendrendement Sectorgemiddelde	2.76% 2.38%
Volgende Winsten	4 aug 2026
Volgende dividenddatum	8 jul 2026
Volgende Ex Dividend datum	15 jun 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	12B 284B
Vorige openingsprijs	120.73
Vorige sluitingsprijs	119.77

Nieuwssentiment

By Acuity

32%

68%

72 / 344 Rangschikking in Healthcare

Merck & Co Inc. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

30 apr 2026, 14:20 UTC

Winsten

Merck 1Q Sales Rise on Continued Keytruda Growth -- Update

30 apr 2026, 10:45 UTC

Winsten

Merck 1Q Sales Rise on Continued Keytruda Growth

5 mei 2026, 18:12 UTC

Winsten

BioNTech to Slash 22% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5 mei 2026, 13:54 UTC

Winsten

BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5 mei 2026, 12:48 UTC

Acquisities, Fusies, Overnames

Merck Cites Costs Associated With Advancing TERN-701 and Financing >MRK

5 mei 2026, 12:48 UTC

Acquisities, Fusies, Overnames

Merck: GAAP and Adj EPS Expected to Be Negatively Impacted by About 12c/Shr in 2026 >MRK

5 mei 2026, 12:47 UTC

Acquisities, Fusies, Overnames

Merck: Transaction Expected to Be Accounted for as Asset Acquisition, Resulting in Chg of About $5.8 B, or $2.35/Shr, Included in 2Q and FY26 Results >MRK

5 mei 2026, 12:45 UTC

Acquisities, Fusies, Overnames

Merck Completes Acquisition Of Terns Pharmaceuticals, Inc. >MRK TERN

1 mei 2026, 18:35 UTC

Winsten

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1 mei 2026, 14:53 UTC

Winsten

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

30 apr 2026, 13:27 UTC

Winsten

Merck Stock Falls After Earnings. It's Working on Ways to Blunt Future Lost Keytruda Sales. -- Barrons.com

30 apr 2026, 10:47 UTC

Winsten

Update: Merck Stock Rises on Earnings. These Problems Loom Larger Than Keytruda Patent Cliff. -- Barrons.com

30 apr 2026, 10:30 UTC

Winsten

Merck: Also Anticipate EPS Will Be Negatively Affected by About 12c Over Remainder of 2026 Following Close of Terns Deal >MRK

30 apr 2026, 10:30 UTC

Winsten

Merck Raises 2026 View To Adj EPS $5.04-Adj EPS $5.16 Vs Prior View $5-$5.15 >MRK

30 apr 2026, 10:30 UTC

Winsten

Merck: 2026 Outlook Doesn't Reflect Any Impact From Proposed Acquisition of Terns Pharmaceuticals, Which Is Expected to Close in May and Result in One-Time Charge of About $2.35/Shr >MRK

30 apr 2026, 10:30 UTC

Winsten

Merck: Sales Outlook Includes Positive Impact From Forex of About 1% at Mid-April 2026 Exchange Rates >MRK

30 apr 2026, 10:30 UTC

Winsten

Merck: Adj EPS Outlook Also Reflects One-Time Charge of $3.62/Shr for Acquisition of Cidara >MRK

30 apr 2026, 10:30 UTC

Winsten

Merck: Adj EPS Outlook Includes Positive Impact From Forex of About 10c/Shr at Mid-April 2026 Exchange Rates >MRK

30 apr 2026, 10:30 UTC

Winsten

Merck Narrows 2026 View To Sales $65.8B-$67B Vs Prior View $65.5B-$67B >MRK

30 apr 2026, 10:30 UTC

Winsten

Merck: Latest 1Q Includes Charge of $3.62/Share for the Acquisition of Cidara >MRK

30 apr 2026, 10:30 UTC

Winsten

Merck: 1Q Gardasil/Gardasil 9 Sales Also Reflect Lower Sales in U.S. Primarily Due to Unfavorable Public-Sector Purchasing Patterns, Partially Offset by Higher Net Pricing >MRK

30 apr 2026, 10:30 UTC

Winsten

Merck 1Q Gardasil/Gardasil 9 Sales Down 19% >MRK

30 apr 2026, 10:30 UTC

Winsten

Merck: Lower 1Q Januvia/Janumet Sales Due to Lower Demand and Net Pricing in U.S., Lower Demand in China and Most Other International Markets Due to Generic Competition >MRK

30 apr 2026, 10:30 UTC

Winsten

Merck: Pleased With Progress and Excited for What's Ahead, as We Enter Particularly Robust Period of Phase 3 Data Readouts and Deliver on Promise of Our Pipeline for Patients >MRK

30 apr 2026, 10:30 UTC

Winsten

Merck 1Q Winrevair Sales $525M, Up 88%, Reflecting Continued Uptake in U.S. and Early Launch Uptake in Certain Intl Mkts, Especially Japan and Europe >MRK

30 apr 2026, 10:30 UTC

Winsten

Merck: 1Q Animal Health Sales Growth Attributable to Performance in Both Livestock and Companion Animal Product Portfolios >MRK

30 apr 2026, 10:30 UTC

Winsten

Merck: Lower 1Q Gardasil/Gardasil 9 Sales Primarily Due to Lower Demand in China as Well as Lower Sales in Japan Following National Catch-Up Immunization Program >MRK

30 apr 2026, 10:30 UTC

Winsten

Merck 1Q Pharmaceutical Sales Up 5% >MRK

30 apr 2026, 10:30 UTC

Winsten

Merck 1Q Animal Health Sales Up 13% >MRK

30 apr 2026, 10:30 UTC

Winsten

Merck 1Q Sales $16.29B >MRK

Peer Vergelijking

Prijswijziging

Merck & Co Inc. Prognose

Koersdoel

By TipRanks

13.01% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 136.5 USD 13.01%

Hoogste 179 USD

Laagste 112 USD

Gebaseerd op 19 Wall Street-analisten die 12-maands prijsdoelen bieden voor Merck & Co Inc. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

19 ratings

Buy

Hold

Sell

Gebaseerd op 19 analisten die aandelenratings hebben gegeven aan Merck & Co Inc. - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

72 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.